InterCure Ltd. (NASDAQ: INCR – Get a rating) saw a significant drop in short-term interest rates in June. As of June 15, there was short interest totaling 101,200 shares, down 26.7% from the May 31 total of 138,000 shares. Currently, 0.4% of the company’s shares are sold short. Based on an average daily trading volume of 59,900 shares, the day-to-cover ratio is currently 1.7 days.
Several institutional investors and hedge funds have recently changed their INCR holdings. Citigroup Inc. increased its equity stake in InterCure to 9,567.9% in Q1. Citigroup Inc. now owns 5,124 shares of the company valued at $36,000 after purchasing an additional 5,071 shares during the period. Davy Global Fund Management Ltd acquired a new position in shares of InterCure in Q1 worth approximately $152,000. Goldman Sachs Group Inc. acquired a new position in shares of InterCure in Q3 valued at approximately $283,000. ETF Managers Group LLC acquired a new position in shares of InterCure in Q4 valued at approximately $3,592,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in InterCure stock in Q4 valued at approximately $5,423,000. Institutional investors hold 9.34% of the company’s shares.
INCR stock traded down $0.07 at midday on Friday, hitting $5.86. 1,341 shares of the stock were traded, against an average volume of 33,830. The company has a current ratio of 1.67, a quick ratio of 1.26 and a leverage ratio of 0.07. InterCure has a 52-week low of $4.50 and a 52-week high of $8.77. The company has a market capitalization of $250.46 million and a P/E ratio of 48.83. The stock’s fifty-day moving average is $6.26 and its 200-day moving average is $6.51.
InterCure (NASDAQ:INCR – Get a rating) last released its quarterly earnings data on Monday, May 16. The company reported EPS of $0.11 for the quarter. InterCure had a net margin of 5.38% and a return on equity of 3.23%. The company had revenue of $27.29 million in the quarter.
About InterCure (Get a rating)
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing and distribution of medical cannabis products in Israel and abroad. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in the biomedical sector.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in InterCure right now?
Before you consider InterCure, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and InterCure wasn’t on the list.
While InterCure currently has an “N/A” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here